BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24739824)

  • 1. Mutation profiling in gallbladder cancer in Indian population.
    Kumari N; Corless CL; Warrick A; Beadling C; Nelson D; Neff T; Krishnani N; Kapoor VK
    Indian J Pathol Microbiol; 2014; 57(1):9-12. PubMed ID: 24739824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
    BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
    Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
    Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
    Deshpande V; Nduaguba A; Zimmerman SM; Kehoe SM; Macconaill LE; Lauwers GY; Ferrone C; Bardeesy N; Zhu AX; Hezel AF
    BMC Cancer; 2011 Feb; 11():60. PubMed ID: 21303542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Protein p53 and K-ras Gene Mutations in Peruvian Patients with Gallbladder Cancer.
    Vidaurre T; Casavilca S; Montenegro P; Gomez H; Calderón M; Navarro J; Aramburu J; Poquioma E; Tsuchiya Y; Asai T; Ajioka Y; Sato A; Ikoma T; Nakamura K
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):289-294. PubMed ID: 30678452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Changes of P
    Shukla SK; Singh G; Shahi KS; Bhuvan ; Pant P
    J Gastrointest Cancer; 2020 Jun; 51(2):552-559. PubMed ID: 31396884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
    PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
    Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
    Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
    Byron SA; Gartside M; Powell MA; Wellens CL; Gao F; Mutch DG; Goodfellow PJ; Pollock PM
    PLoS One; 2012; 7(2):e30801. PubMed ID: 22383975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.